je.st
news
Amarantus Requests Rare Pediatric Disease Designation From FDA
2016-02-09 01:17:54| drugdiscoveryonline News Articles
Amarantus BioScience Holdings, Inc.(OTCQB: AMBS),a biotechnology company focused on developing products for Regenerative Medicine, Neurology and Orphan Diseases, announced that it has requested Rare Pediatric Disease Designation (RPDD) from the US Food and Drug Administration (FDA) for treating retinitis pigmentosa (RP) with MANF.
Tags: disease
requests
rare
designation
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||||||||||||||||||||
|
|
||||||||||||||||||||